Harfst & Associates’s AbbVie ABBV Stock Holding History

Harfst & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$652K	Sell	2,590 -31	-1%	-$6.67K	0.1%	85
2026 Q1	$570K	Hold	2,621	–	–	0.1%	96
2025 Q4	$599K	Hold	2,621	–	–	0.11%	88
2025 Q3	$607K	Sell	2,621 -10	-0.4%	-$2.04K	0.11%	85
2025 Q2	$488K	Sell	2,631 -10	-0.4%	-$1.86K	0.1%	80
2025 Q1	$553K	Hold	2,641	–	–	0.13%	92
2024 Q4	$469K	Hold	2,641	–	–	0.1%	64
2024 Q3	$522K	Sell	2,641 -40	-1%	-$7.46K	0.12%	72
2024 Q2	$460K	Hold	2,681	–	–	0.11%	81
2024 Q1	$488K	Hold	2,681	–	–	0.12%	80
2023 Q4	$415K	Hold	2,681	–	–	0.11%	69
2023 Q3	$400K	Sell	2,681 -235	-8%	-$34.5K	0.11%	73
2023 Q2	$393K	Buy	2,916 +235	+9%	+$34.5K	0.1%	74
2023 Q1	$427K	Hold	2,681	–	–	0.12%	92
2022 Q4	$433K	Hold	2,681	–	–	0.13%	93
2022 Q3	$360K	Hold	2,681	–	–	0.11%	94
2022 Q2	$410K	Hold	2,681	–	–	0.12%	91
2022 Q1	$434K	Sell	2,681 -55	-2%	-$7.99K	0.1%	100
2021 Q4	$370K	Buy	2,736 +55	+2%	+$6.5K	0.09%	99
2021 Q3	$289K	Hold	2,681	–	–	0.08%	111
2021 Q2	$301K	Hold	2,681	–	–	0.09%	113
2021 Q1	$290K	Hold	2,681	–	–	0.09%	126
2020 Q4	$287K	Hold	2,681	–	–	0.11%	106
2020 Q3	$234K	Buy	2,681 +16	+0.6%	+$1.51K	0.1%	105
2020 Q2	$261K	Hold	2,665	–	–	0.11%	93
2020 Q1	$203K	Hold	2,665	–	–	0.1%	95
2019 Q4	$235K	Hold	2,665	–	–	0.09%	95
2019 Q3	$201K	Buy	+2,665	New	+$183K	0.08%	95
2019 Q2	–	Sell	-2,695	Closed	-$217K	–	94
2019 Q1	$217K	Hold	2,695	–	–	0.09%	94
2018 Q4	$248K	Hold	2,695	–	–	0.12%	80
2018 Q3	$254K	Hold	2,695	–	–	0.11%	75
2018 Q2	$249K	Hold	2,695	–	–	0.11%	73
2018 Q1	$255K	Buy	2,695 +475	+21%	+$52.2K	0.1%	72
2017 Q4	$214K	Buy	+2,220	New	+$209K	0.09%	80
2017 Q3	–	Sell	-2,220	Closed	-$160K	–	84
2017 Q2	$160K	Sell	2,220 -592	-21%	-$39.8K	0.06%	89
2017 Q1	$183K	Sell	2,812 -1,334	-32%	-$83.9K	0.08%	81
2016 Q4	$259K	Sell	4,146 -145	-3%	-$8.85K	0.13%	59
2016 Q3	$270K	Buy	4,291 +387	+10%	+$25.1K	0.14%	56
2016 Q2	$241K	Sell	3,904 -1,872	-32%	-$114K	0.1%	92
2016 Q1	$329K	Sell	5,776 -104	-2%	-$5.8K	0.21%	44
2015 Q4	$348K	Buy	5,880 +300	+5%	+$17.3K	0.14%	78
2015 Q3	$304K	Buy	5,580 +726	+15%	+$47.3K	0.13%	80
2015 Q2	$326K	Buy	+4,854	New	+$317K	0.18%	40

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Harfst & Associates's ABBV Position: Q2 2026 in Review

Harfst & Associates reduced its AbbVie (ABBV) stake by 1.2% in Q2 2026, selling an estimated $6.67K and leaving 2,590 shares worth $652K. The position accounts for 0.1% of the portfolio, ranked #85.

Harfst & Associates first reported a position in ABBV in Q2 2015 and has held it in 43 quarters since. 4,194 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Harfst & Associates held 2,590 shares of AbbVie worth $652K as of Q2 2026.
Harfst & Associates sold 31 AbbVie shares in Q2 2026, an estimated $6.67K.
AbbVie made up 0.1% of Harfst & Associates's portfolio in Q2 2026, its #85 holding.
Harfst & Associates first reported a position in AbbVie in Q2 2015 and has held it in 43 quarters since.
4,194 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Harfst & Associates's 13F filing for Q2 2026, filed 31 Jul 2026.